Liquidia Corporation (LQDA)
NASDAQ: LQDA
· Real-Time Price · USD
15.75
0.49 (3.21%)
At close: May 12, 2025, 3:59 PM
16.27
3.30%
Pre-market: May 13, 2025, 05:25 AM EDT
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.
It also distributes generic treprostinil injection in the United States.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Liquidia Corporation
| Country | United States |
| IPO Date | Jul 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 170 |
| CEO | Dr. Roger A. Jeffs Ph.D. |
Contact Details
Address: 419 Davis Drive Morrisville, North Carolina United States | |
| Website | https://www.liquidia.com |
Stock Details
| Ticker Symbol | LQDA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001819576 |
| CUSIP Number | 53635D202 |
| ISIN Number | US53635D2027 |
| Employer ID | 85-1710962 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Roger A. Jeffs Ph.D. | Chief Executive Officer & Director |
| Michael Kaseta | Chief Operating Officer & Chief Financial Officer |
| Dr. Rajeev Saggar M.D. | Chief Medical Officer |
| Frank Bartolini | Senior Vice President of Market Access |
| Harold Alterson | Senior Vice President of Quality |
| Jason Adair | Chief Business Officer |
| Michael Hunter | Senior Vice President of Manufacturing Operations |
| Russell Schundler | General Counsel & Corporate Secretary |
| Sarah Krepp SPHR | Senior Vice President of People & Culture |
| Scott Moomaw | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | 8-K | Current Report |
| May 08, 2025 | 10-Q | Quarterly Report |
| May 08, 2025 | 8-K | Current Report |
| May 08, 2025 | 8-K | Current Report |
| May 05, 2025 | 8-K | Current Report |
| Apr 30, 2025 | 4 | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 23, 2025 | 4 | Filing |